Compare DexCom, Inc. (DXCM) vs NetFlix Inc (NFLX) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Netflix (NFLX) trades at $73.53, down 0.41% on the day and approaching its 52-week low. The technical picture remains bearish with strong selling pressure, while fundamentals show robust revenue growth to $45.18B in 2025 and net income of $10.98B. Recent earnings beat expectations with Q1 2026 EPS of $1.23 versus $0.76 expected, though the stock faces negative momentum amid concerns about growth sustainability.

Despite current bearish technicals, Netflix maintains strong fundamentals with 65% analyst buy ratings and a $103.64 consensus price target suggesting 41% upside. Key opportunities include advertising revenue scaling toward $3B by 2026 and expanding global market share. Risks include intense streaming competition and execution challenges in new business verticals like live sports and gaming.